You are here

Home » Content

Pulmoner Tromboembolide Genetik Risk Faktörleri (Beş Olgu Nedeniyle)

Genetic Risk Factors In Pulmonary Thromboemboli (Reports of Five Cases)

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Pulmonary thromboembolus is a disease with high mortality and morbidity. In addition to well known and frequent risk factors, there are some rare congenital predisposing factors. In five of 43 patients (11.6%) diagnosed as pulmonary embolus between 1998 and 2001 in our clinic we detected a genetic risk factor for venous thromboemboli. Except one patient, there were no formerly known genetic risk factor. Due to our results, it can be proposed that the genetical predisposition should be searched in patients who developed venous thromboemboli without any known risk factor. We discussed 3 patients with antiphospholipid syndrome, one patient with protein C deficiency and one patient with protein S deficiency and activated protein C resistance (APC-R), in total 5 cases, with regard to current literature.
Bookmark/Search this post with
Abstract (Original Language): 
Pulmoner tromboemboli mortalite ve morbiditesi yüksek bir hastalıktır. Hastalık için bilinen ve sık görülen risk faktörlerinin yanı sıra, kongenital predispozisyon yaratan nadir durumlar da vardır. Kliniğimizde 1998-2001 yıllarında takip edilen pulmoner tromboembolili 43 hastanın beşinde (%11.6) venöz tromboemboli için genetik risk faktörü saptadık. Hastaların biri dışında hiçbirisinde daha önceden bilinen bir genetik risk faktörü yoktu. Bu yüzden; bilinen bir risk faktörü olmadığı halde, venöz tromboemboli gelişen hastalarda genetik yatkınlık sebepleri araştırılmalıdır. Biz antifosfolipid sendromlu üç, protein C eksikliği olan bir ve protein S eksikliği- aktive protein C rezistansla (APC-R) bir olguda gelişen pulmoner tromboembolili toplam beş olguyu, ilgili literatür eşliğinde tartıştık.
FULL TEXT (PDF): 
PDF icon arastirmax-pulmoner-tromboembolide-genetik-risk-faktorleri-bes-olgu-nedeniyle.pdf
  • 3
215-218
  • Turkish

REFERENCES

References: 

1. Herold CJ, Bankier AA, Burghuber OC, et al. Pulmonary embolism: Pulmonary vascular disorders, vasculities, and hemorrhage. In: Albert RK, Spiro SG, Jett JR, eds. Comprehensive respiratory medicine. Philadelphia: Mosby, 1999: 1-12.
2. Murin S, Marelich GP, Arroliga AC, et al. Hereditary thrombophilia and venous thromboembolism. Am J Respir Ctit Care Med 1998; 158: 1369-73.
3. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia Part I. Thromb
Haemoast 1996; 76: 651-2.
4. Korkmaz C, Harmanci E, Metintas I, Gulbas Z. Antiphospholipid syndrome associated with intestinal amoebiasis. Scand J Infect Dis 2001; 33: 938-40.
5.
Gülha
n M, Özyılmaz A, Ertürk A, ve ark. Protein S eksikliğine bağlı tekrarlayan tromboemboli ve pulmoner hipertansiyon (Olgu Sunumu).Toraks Dergisi 2002; 3: 53 (PS-202).
6.
Yıldırı
m M, Ardıç S, Taştan Dursun Ç, ve ark. Protein C ve S eksikliğinin birlikte olduğu bir pulmoner tromboemboli olgusu. Toraks Dergisi 2002; 3: 64 (PS-248).
7. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia Part II. Thromb
Haemoast 1996; 76: 824-34.
8. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
9.
Levin
e JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med
2002; 346: 752-63.
1 0. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun
2000; 15:145-51.
11. Aung W, Murata Y, Ishida R, Shibuya H. Comparison of lung perfusion scintigraphic findings in pulmonary thromboembolism in systemic lupus erythematosus, SLE plus antiphospholipid syndrome, and primary antiphospholipid syndrome. Nucl Med
Commun 2000; 21: 299-304.
1 2. Love PE, Santoro SA. Antiphospholipid antibodies, anticardiolipin and the lupus anticoagulant in the systemic lupus erythematosus (SLE) and in non SLE disorders.
Ann Intern Med 1990; 112: 682-98.
13. Weber M, Hayem G, De Bandt M, et al. The family history of patients with primary or secondary antiphospholipid syndrome (APS). Lupus 2000;9:258-63.
1 4. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective
study from the Italian registry. Am J Med 1996; 100: 530-6.
15. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
1 6. Kolsuz M. Venöz trombüs ve tromboemboli risk faktörleri. In: Metintaş M. Pulmoner tromboemboli. Eskişehir: ASD Toraks Yayınları: 2001; 21-41.
1 7. Witlin AG, Mattar FM, Saade GR, et al. Presentation of venous thromboembolism
during pregnancy. Am J Obstet Gynecol 1999; 181: 1118-21.
1 8. Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of
mutations, 1995 update. Thromb Res 1995; 77: 1-43.
19. De Stefano V, Finazzi G, Mannucci G. Inherited Thrombophilia:pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
20. Engesser L, Broekmans AW, Briet E, et al. Hereditary protein S deficiency: clinical
manifestations. Ann Intern Med 1987; 106: 677-82.
21. Dahlback B. Inherited Thrombophilia: resistance to activated protein C as a pathogenetic factor of venous thromboembolism. Blood 1995; 85: 607-14.

Thank you for copying data from http://www.arastirmax.com